share_log

Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1

Morgan Stanley Upgrades C4 Therapeutics to Equal-Weight, Lowers Price Target to $1

摩根士丹利將C4 Therapeutics上調至同等權重,將目標股價下調至1美元
Benzinga ·  2023/11/06 07:51

Morgan Stanley analyst Terence Flynn upgrades C4 Therapeutics (NASDAQ:CCCC) from Underweight to Equal-Weight and lowers the price target from $3 to $1.

摩根士丹利分析師特倫斯·弗林將C4 Therapeutics(納斯達克股票代碼:CCCC)從減持上調至同等權重,並將目標股價從3美元下調至1美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論